Chemical inhibitors of 2310040A07Rik utilize various mechanisms to attenuate the activity of this protein through interference with specific signaling pathways. Staurosporine serves as a broad-spectrum protein kinase inhibitor; by hindering the activity of these kinases, it can prevent the phosphorylation events necessary for 2310040A07Rik function, if such function is phosphorylation-dependent. Similarly, Bisindolylmaleimide I targets Protein Kinase C, and its inhibitory effect on PKC could disrupt any 2310040A07Rik-related signaling processes that rely on PKC activity. LY294002, as a PI3K inhibitor, can impede any PI3K/AKT pathway interactions involving 2310040A07Rik, thereby halting subsequent AKT phosphorylation and its downstream effects. Rapamycin specifically inhibits mTOR, a key regulator of cell growth and metabolism; if 2310040A07Rik operates within mTOR-related pathways, the inhibition of mTOR would effectively suppress its activity.
Further down the list, PD98059, SB203580, and SP600125 target MAP kinase pathways, each with specificity to MEK1/2, p38 MAPK, and JNK, respectively. If 2310040A07Rik is active within these pathways, these inhibitors can prevent the kinase signaling cascades from propagating, thereby inhibiting 2310040A07Rik activity. PP2 and Dasatinib both inhibit Src family kinases, with Dasatinib also targeting c-KIT; they can block the signaling pathways involving these kinases that 2310040A07Rik may be part of. Erlotinib, an EGFR tyrosine kinase inhibitor, can disrupt the EGFR signaling if 2310040A07Rik is regulated by EGFR-mediated processes. Sorafenib's multi-kinase inhibition includes targeting RAF kinases, which are upstream of many signaling cascades; inhibition here would block RAF-dependent signaling involving 2310040A07Rik. Lastly, Sunitinib, as a receptor tyrosine kinase inhibitor, can obstruct pathways that rely on these kinases for signal transduction, which would include any such pathways where 2310040A07Rik is operative, leading to an inhibition of its activity. Through these diverse yet specific mechanisms, each chemical can lead to the inhibition of 2310040A07Rik by interfering with the pathways and signaling mechanisms necessary for its function.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $153.00 $396.00 | 113 | |
Staurosporine can inhibit protein kinases, which could lead to the inhibition of 2310040A07Rik if its function relies on phosphorylation by these kinases. | ||||||
Bisindolylmaleimide I (GF 109203X) | 133052-90-1 | sc-24003A sc-24003 | 1 mg 5 mg | $105.00 $242.00 | 36 | |
As a specific inhibitor of Protein Kinase C (PKC), this chemical can inhibit 2310040A07Rik by hindering PKC-dependent signaling pathways that the protein is involved in. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 inhibits PI3K, and if 2310040A07Rik is active in the PI3K/AKT pathway, this inhibition can prevent the protein's function by blocking downstream signaling. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin inhibits mTOR, which is a central component of cell growth and metabolism regulation; inhibition of mTOR can suppress the activity of 2310040A07Rik if it is involved in mTOR signaling pathways. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
Through selective inhibition of MEK1/2, PD98059 can inhibit 2310040A07Rik if the protein's function is regulated via the MEK/ERK pathway, by preventing MEK/ERK signaling cascade. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580 targets p38 MAPK, and can inhibit 2310040A07Rik activity if the protein is associated with the p38 MAPK signaling pathway by inhibiting this specific kinase signaling. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 inhibits JNK, thus can inhibit 2310040A07Rik if it is involved in JNK-mediated signaling pathways by blocking JNK signaling. | ||||||
PP 2 | 172889-27-9 | sc-202769 sc-202769A | 1 mg 5 mg | $94.00 $227.00 | 30 | |
PP2 is an inhibitor of Src family tyrosine kinases and can inhibit 2310040A07Rik by interfering with Src family kinase-dependent signaling pathways. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $70.00 $145.00 | 51 | |
Dasatinib, which inhibits Src family kinases and c-KIT, can inhibit 2310040A07Rik by blocking the kinase signaling pathways that the protein operates in. | ||||||
Erlotinib, Free Base | 183321-74-6 | sc-396113 sc-396113A sc-396113B sc-396113C sc-396113D | 500 mg 1 g 5 g 10 g 100 g | $87.00 $135.00 $293.00 $505.00 $3827.00 | 42 | |
Erlotinib targets EGFR tyrosine kinase and can inhibit 2310040A07Rik by disrupting EGFR signaling pathways if 2310040A07Rik's function is regulated by EGFR-mediated signaling. | ||||||